Abbvie: How is a new aesthetics strategy targeting hesitant patients?
Reading Time: 2 minutes
The European Commission approved the neurotoxin Boey (trenibotulinumtoxinE) from Abbvie's subsidiary Allergan Aesthetics on July 17, 2026. With a short duration of action of two to three weeks, the company strategically positions the product to attract new buyer segments without prior experience. Following the recent approval in Canada, the next step for commercial launch in Europe will take place in the coming months. Strategic Expansion of the Portfolio The pharmaceutical company Abbvie (ABBV) received European approval for the product...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
